Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib + VP16 + Trastuzumab in HER2+ MBC
NCT05955170Phase 2Recruiting
- Sponsor
- Institut Curie
- Start
- Dec 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucatinib in HER2-positive breast cancer, sponsored by Institut Curie. Started Dec 2023; status: recruiting.
02
Drugs
tucatinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05955170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05955170.